| Income Statement | 2025-09-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Total other income (expense), net | -164,174 | -938,633 | -216,801 | -63,520 |
| Loss before taxes | -4,837,738 | -54,067,346 | -430,183 | -354,310 |
| Net loss | -4,837,738 | -54,067,346 | -430,183 | -354,310 |
| Net loss available to common stockholders | - | -54,067,346 | -430,183 | -354,310 |
| Unrealized foreign currency translation gain (loss) | 17,044 | -27,311 | 321,230 | -98,943 |
| Total other comprehensive income (loss) | 17,044 | -27,311 | 321,230 | -98,943 |
| Total comprehensive loss | -4,820,694 | -54,094,657 | -108,953 | -453,253 |
| Basic net loss per share | -0.39 | -12.5 | -32.23 | 0 |
| Basic weighted average shares outstanding | 12,331,526 | 4,325,994 | 13,347 | 590,937,498 |
| Diluted net loss per share | -0.39 | -12.5 | -32.23 | 0 |
| Diluted weighted average shares outstanding | 12,331,526 | 4,325,994 | 13,347 | 590,937,498 |
Propanc Biopharma, Inc. (PPCB)
Propanc Biopharma, Inc. (PPCB)